Nowadays, bortezomib, a proteasome inhibitor, is widely used in treatment of newly diagnosed or relapsed multiple myeloma. The aim of this study was to analyze efficiency of bortezomib retreatment in patients with relapsed or refractory multiple myeloma. From 2004 to 2016, 283 patients were retrospectively evaluated at all hematological centers in the Czech Republic. Bortezomib was administered at the standard dosing and in combined therapy with corticosteroids, chemotherapy or thalidomide. Before bortezomib retreatment, 61% of patients received previous lenalidomide treatment, 40.6% autologous transplantation, and median number of prior lines of therapy was three. In total, 21% of patients were refractory to the first bortezomib treatment. In bortezomib retreatment, overall response rate was 34.5%, median progression-free survival was 7.8 months (95% CI: 6.7-8.9), median duration of response was 10.5 months (95% CI: 8.0-13.0) and median overall survival was 20.3 months (95% CI: 17.9-22.7). Grade 3-4 adverse events included thrombocytopenia, neutropenia, anemia and infection. Neuropathy grade 2 or higher occurred in 19.4% of patients. We conclude that bortezomib retreatment is an effective and safe therapeutic alternative for relapsed or refractory multiple myeloma patients.
- MeSH
- bortezomib terapeutické užití MeSH
- lidé MeSH
- mnohočetný myelom farmakoterapie MeSH
- opakovaná terapie MeSH
- protokoly antitumorózní kombinované chemoterapie MeSH
- recidiva MeSH
- retrospektivní studie MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Česká republika MeSH
OBJECTIVE: To predict the real-world (RW) cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in relapsed multiple myeloma (MM) patients after one to three prior therapies. METHODS: A partitioned survival model that included three health states (progression-free, progressed disease and death) was built. Progression-free survival (PFS), overall survival (OS) and time to discontinuation (TTD) data for the Rd arm were derived using the Registry of Monoclonal Gammopathies in the Czech Republic; the relative treatment effects of KRd versus Rd were estimated from the phase 3, randomised, ASPIRE trial, and were used to predict PFS, OS and TTD for KRd. The model was developed from the payer perspective and included drug costs, administration costs, monitoring costs, palliative care costs and adverse-event related costs collected from Czech sources. RESULTS: The base case incremental cost effectiveness ratio for KRd compared with Rd was €73,156 per quality-adjusted life year (QALY) gained. Patients on KRd incurred costs of €117,534 over their lifetime compared with €53,165 for patients on Rd. The QALYs gained were 2.63 and 1.75 for patients on KRd and Rd, respectively. CONCLUSIONS: Combining the strengths of randomised controlled trials and observational databases in cost-effectiveness models can generate policy-relevant results to allow well-informed decision-making. The current model showed that KRd is likely to be cost-effective versus Rd in the RW and, therefore, the reimbursement of KRd represents an efficient allocation of resources within the healthcare system.
- MeSH
- analýza nákladů a výnosů * MeSH
- dexamethason farmakologie MeSH
- kvalitativně upravené roky života MeSH
- lenalidomid farmakologie MeSH
- lidé MeSH
- lokální recidiva nádoru farmakoterapie etiologie MeSH
- mnohočetný myelom farmakoterapie etiologie mortalita MeSH
- náklady na léky MeSH
- oligopeptidy farmakologie MeSH
- přežití po terapii bez příznaků nemoci MeSH
- protokoly antitumorózní kombinované chemoterapie MeSH
- registrace MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- randomizované kontrolované studie MeSH
- Geografické názvy
- Česká republika MeSH
Monoclonal gammopathy of undetermined significance (MGUS) is a known precursor of more serious cancers, such as multiple myeloma (MM), Waldenström macroglobulinemia (MW) and other lymphoproliferative disorders. Using 18F-FDG PET/CT, we aimed to evaluate its benefit in early detection of various accompanying disorders and illnesses in MGUS patients. We prospectively analyzed the diagnostic relevance of 18F-FDG PET/CT in 390 newly diagnosed MGUS patients. On 18F-FDG PET/CT scans, the presence of focal or diffuse areas of detectable increased tracer uptake was recorded in 37 (9.5%) MGUS patients. The most frequent pathology was lymphadenopathy (3.8%), followed by thyroid diseases (2.1%), rheumatic diseases (1.8%), and other solid malignancies (1.5%). These results have major implications for confirmed associations of MGUS with numerous malignant and non-malignant disorders. We believe that 18F-FDG PET/CT imaging in newly diagnosed MGUS patients may be useful in early detection of other serious pathologies, not only in predicting progression of MGUS to active MM, and should be strongly recommended if available.
Histiocytóza z Langerhansových buněk má velmi pestré klinické projevy a u jednotlivých pacientů odlišnou míru agresivity. Po stanovení diagnózy je zásadní, stejně jako u ostatních maligních chorob, určit rozsah choroby, zjistit, které z orgánů jsou postiženy a v jaké míře. V případě jednoho ložiska lze použít lokální terapii (operační řešení, nebo instilaci metylprednisolonu do ložiska). Kožní postižení reaguje na světloléčbu (PUVA, případně electron beam irradiation). V případě izolovaného kožního postižení byly také popsány remise po léčbě thalidomidem nebo metotrexátem. V případně multisystémového postižení se u dospělých preferuje léčba 2-chlorodeoxyadenosinem (kladribinem) v monoterapii, méně často v kombinaci s cytosin-arabinosidem. Pro velmi agresivní formy lze použít chemoterapeutická schémata s etoposidem, které se jinak používají pro léčbu lymfomů. V případě rezistentních forem lze po domluvě s transplantačním centrem použít vysokodávkovanou chemoterapii s autologní či alogenní transplantací krvetvorných buněk. U pacientů s mutací genu BRAF V600E byla prokázána účinnost vemurafenibu či dabrafenibu, které jsou v ČR registrované pro léčbu diseminovaného melanomu a bylo by možné při prokázání této mutace a při rezistenci na přechozí léčbu požádat plátce zdravotní péče o schválení úhrady i pro tuto diagnózu.
Langerhans cell histiocytosis has diverse clinical manifestations and the aggressiveness of its course varies. As in the case of other malignant diseases, involvement of other organs must be determined once the diagnosis has been made. Local treatment may suffice in the case of a single lesion (surgery, instillation of methylprednisolone within the lesion). Skin involvement responds to phototherapy (PUVA or electron beam irradiation). Remissions following the administration of thalidomide or methotrexate have been described in cases of isolated skin involvement. In adults, 2-cholorodeoxyadenosine (cladribine) in monotherapy and less often in combination with cytosine-arabinoside is the treatment of choice in the case of multi-system involvement. Extremely aggressive forms may be treated with combined chemotherapy regimens that include etoposide as in the case of lymphomas. In resistant cases, patients may be referred to transplant centres and undergo high-dose chemotherapy with autologous or allogeneic stem cell transplantation. Patients with the BRAF V600E gene mutation have been shown to respond to vemurafenib or dabrafenib, which are registered in the Czech Republic for the treatment of disseminated melanoma. On demonstrating this mutation and documenting resistance to prior therapy, it would be possible to request reimbursement of these agents from the health insurance company.
- Klíčová slova
- dabrafenib,
- MeSH
- glukokortikoidy terapeutické užití MeSH
- histiocytóza z Langerhansových buněk * diagnóza patologie terapie MeSH
- hodnocení léčiv MeSH
- imidazoly MeSH
- kladribin terapeutické užití MeSH
- lidé MeSH
- příznaky a symptomy ústrojí dýchacího MeSH
- příznaky a symptomy MeSH
- vemurafenib terapeutické užití MeSH
- Check Tag
- lidé MeSH
The main goal was to find a simple prognostic to evaluate overall survival of patients older than 65 years of age with myeloma. Retrospective registry-based analysis from the Registry of Monoclonal Gammopathies was conducted. Patients over 65 years with symptomatic myeloma were included. The four major parameters with impact on survival were identified: male gender, age > 75, creatinine > 152 μmol/L, and ECOG performance status 2-4. The patients were scored as good (0 points), intermediate good (1 point), intermediate poor (2 points), poor (3-4 points). Patients (1410 MM) were included. Median OS (months) was 65.7 (95% CI 49.8-81.7) for good, 51.0 (44.1-57.8) for intermediate good, 32.2 (26.2-38.2) for intermediate poor, and 18.9 (15.1-22.7) for poor. The differences in OS were statistically significant (p < 0.0001). Good score was used as reference for hazard ratios, which for each other score were 1.43 (1.09-1.84) for intermediate good, 2.58 (2.00-3.33) for intermediate poor, and 3.88 (2.94-5.10) for poor. Time to progression showed medians (months) 20.5 (17.4-62.4) for good, 19.3 (17.0-21.7) for intermediate good, 19.6 (16.2-23.0) for intermediate poor, and 13.0 (10.8-15.2) for poor. The suggested scoring system provides readily available information about the prognosis of MM patients above 65 years.
- MeSH
- lidé MeSH
- míra přežití MeSH
- mnohočetný myelom mortalita terapie MeSH
- přežití po terapii bez příznaků nemoci MeSH
- registrace * MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- věkové faktory MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- multicentrická studie MeSH
The randomized phase 3 study ENDEAVOR demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (MM). We conducted a preplanned subgroup analysis of ENDEAVOR to evaluate Kd vs Vd by cytogenetic risk. Of 785 patients with known cytogenetics, 210 (27%) had high-risk cytogenetics (Kd, n=97 (25%); Vd, n=113 (28%)) and 575 (73%) had standard-risk cytogenetics (Kd, n=284 (75%); Vd, n=291 (72%)). Median PFS in the high-risk group was 8.8 months for Kd vs 6.0 months for Vd (hazard ratio (HR), 0.65; 95% confidence interval (CI), 0.45-0.92; P=0.0075). Median PFS in the standard-risk group was not estimable for Kd vs 10.2 months for Vd (HR, 0.44; 95% CI, 0.33-0.58; P<0.0001). Overall response rates were 72.2% (Kd) vs 58.4% (Vd) in the high-risk group and 79.2% (Kd) vs 66.0% (Vd) in the standard-risk group. In the high-risk group, 15.5% (Kd) vs 4.4% (Vd) achieved a complete response (CR) or better. In the standard-risk group, 13.0% (Kd) vs 7.9% (Vd) achieved ⩾CR. This preplanned subgroup analysis found that Kd was superior to Vd in relapsed or refractory MM, regardless of cytogenetic risk.
- MeSH
- bortezomib aplikace a dávkování MeSH
- chemorezistence účinky léků genetika MeSH
- chromozomální aberace MeSH
- cytogenetické vyšetření MeSH
- dexamethason aplikace a dávkování MeSH
- dospělí MeSH
- indukce remise MeSH
- lidé MeSH
- lokální recidiva nádoru farmakoterapie genetika patologie MeSH
- míra přežití MeSH
- mnohočetný myelom farmakoterapie genetika patologie MeSH
- nádorové biomarkery MeSH
- následné studie MeSH
- oligopeptidy aplikace a dávkování MeSH
- prognóza MeSH
- protokoly antitumorózní kombinované chemoterapie terapeutické užití MeSH
- stupeň nádoru MeSH
- záchranná terapie * MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- multicentrická studie MeSH
- randomizované kontrolované studie MeSH
- srovnávací studie MeSH
The randomized phase 3 ENDEAVOR study (N=929) compared carfilzomib and dexamethasone (Kd) with bortezomib and dexamethasone (Vd) in relapsed multiple myeloma (RMM). We performed a subgroup analysis from ENDEAVOR in patients categorized by number of prior lines of therapy or by prior treatment. Median progression-free survival (PFS) for patients with one prior line was 22.2 months for Kd vs 10.1 months for Vd, and median PFS for patients with ⩾2 prior lines was 14.9 months for Kd vs 8.4 months for Vd. For patients with prior bortezomib exposure, the median PFS was 15.6 months for Kd vs 8.1 months for Vd, and for patients with prior lenalidomide exposure the median PFS was 12.9 months for Kd vs 7.3 months for Vd. Overall response rates (Kd vs Vd) were 81.9 vs 65.5% (one prior line), 72.0 vs 59.7% (⩾2 prior lines), 71.2 vs 60.3% (prior bortezomib) and 70.1 vs 59.3% (prior lenalidomide). The safety profile in the prior lines subgroups was qualitatively similar to that in the broader ENDEAVOR population. In RMM, outcomes are improved when receiving treatment with carfilzomib compared with bortezomib, regardless of the number of prior therapy lines or prior exposure to bortezomib or lenalidomide.
- MeSH
- bortezomib aplikace a dávkování terapeutické užití MeSH
- dexamethason aplikace a dávkování terapeutické užití MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mnohočetný myelom farmakoterapie mortalita MeSH
- oligopeptidy aplikace a dávkování terapeutické užití MeSH
- přežití po terapii bez příznaků nemoci MeSH
- protokoly antitumorózní kombinované chemoterapie terapeutické užití MeSH
- recidiva MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- výsledek terapie MeSH
- záchranná terapie metody mortalita MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- randomizované kontrolované studie MeSH
This randomized, phase III, open-label, multicenter study compared carfilzomib monotherapy against low-dose corticosteroids and optional cyclophosphamide in relapsed and refractory multiple myeloma (RRMM). Relapsed and refractory multiple myeloma patients were randomized (1:1) to receive carfilzomib (10-min intravenous infusion; 20 mg/m(2) on days 1 and 2 of cycle 1; 27 mg/m(2) thereafter) or a control regimen of low-dose corticosteroids (84 mg of dexamethasone or equivalent corticosteroid) with optional cyclophosphamide (1400 mg) for 28-day cycles. The primary endpoint was overall survival (OS). Three-hundred and fifteen patients were randomized to carfilzomib (n=157) or control (n=158). Both groups had a median of five prior regimens. In the control group, 95% of patients received cyclophosphamide. Median OS was 10.2 (95% confidence interval (CI) 8.4-14.4) vs 10.0 months (95% CI 7.7-12.0) with carfilzomib vs control (hazard ratio=0.975; 95% CI 0.760-1.249; P=0.4172). Progression-free survival was similar between groups; overall response rate was higher with carfilzomib (19.1 vs 11.4%). The most common grade ⩾3 adverse events were anemia (25.5 vs 30.7%), thrombocytopenia (24.2 vs 22.2%) and neutropenia (7.6 vs 12.4%) with carfilzomib vs control. Median OS for single-agent carfilzomib was similar to that for an active doublet control regimen in heavily pretreated RRMM patients.
- MeSH
- anemie chemicky indukované MeSH
- cyklofosfamid aplikace a dávkování škodlivé účinky terapeutické užití MeSH
- dospělí MeSH
- hormony kůry nadledvin aplikace a dávkování škodlivé účinky terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- míra přežití MeSH
- mnohočetný myelom komplikace farmakoterapie mortalita MeSH
- neutropenie chemicky indukované MeSH
- oligopeptidy aplikace a dávkování škodlivé účinky terapeutické užití MeSH
- přežití po terapii bez příznaků nemoci MeSH
- recidiva MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- trombocytopenie chemicky indukované MeSH
- záchranná terapie škodlivé účinky metody mortalita MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- multicentrická studie MeSH
- randomizované kontrolované studie MeSH